Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 126

Results For "report"

1829 News Found

Medical devices market in Singapore to reach $3.5 billion in 2022, forecasts GlobalData
News | September 21, 2022

Medical devices market in Singapore to reach $3.5 billion in 2022, forecasts GlobalData

Singapore presents great opportunities for the adoption of technology in healthcare and is open for investments


Fujifilm India launches campaign to promote early diagnosis of TB
Healthcare | September 20, 2022

Fujifilm India launches campaign to promote early diagnosis of TB

The campaign will also focus on providing doorstep TB screening services to facilitate diagnosis


AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData
Drug Approval | September 13, 2022

AstraZeneca likely to see substantial Evusheld uptake in Japan, says GlobalData

Japan’s Ministry of Health, Labour and Welfare (MHLW) has recently approved AstraZeneca's long-acting antibody combination “Evusheld” for the prevention ) and treatment of COVID-19.


Agilent named among top workplaces by Fortune in healthcare
News | September 11, 2022

Agilent named among top workplaces by Fortune in healthcare

85% of Agilent employees who responded to the survey indicated that the company is a great place to work


Boehringer Ingelheim InPedILD Phase III trial showed encouraging results for both primary endpoints
Clinical Trials | September 06, 2022

Boehringer Ingelheim InPedILD Phase III trial showed encouraging results for both primary endpoints

New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease


Centre grants approval of three Bulk Drug Parks
Policy | September 02, 2022

Centre grants approval of three Bulk Drug Parks

The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly


Stelis Biopharma’s flagship facility receives EIR from USFDA
Drug Approval | September 01, 2022

Stelis Biopharma’s flagship facility receives EIR from USFDA

The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise


A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert
Healthcare | September 01, 2022

A 10-year commission with dedicated mission is required to tackle the upsurge of diabetes in India: says Expert

India is at the forefront of research in cardiology worldwide but making indigenous products is what we are lacking & it needs to be improved